About Perceptronix Medical Inc.
Perceptronix Medical Inc.(PMI), provides partnership opportunities for the distribution and test sales of quantitative cytology imaging machine (ClearCyte), software and staining kit (Clear2C) for use in hospitals, universities and commercial laboratories.
PMI's intellectual property which forms the bases of our automated platforms was developed and licensed from BC Cancer Agency in Vancouver. The quantitative cytology system (ClearCyte) measures nuclear genetic material (DNA) of thousands of cell nuclei in matter of few minutes and displays abnormal nuclei for review. This technology help to provide highly information early cancer detection tests including OralAdvance.
PMI Tech, with our dedicated team, works with partner laboratories around the world to improve the detection, localization, diagnosis of various types of cancer.
Accreditation & Market Clearance
Since our incorporation, in 1999, PMI has successfully built an ISO 13485:2003 certified quality management system, developed and manufactured its cytometry technologies, completed multinational clinical trials on tests using these technology platforms. We have also received market clearance from Health Canada, the European Union. Some of our products are also FDA listed as standalone products.
PMI also has a portfolio of patents for out-licensing covering state of the art technologies for cancer visualization.
Perceptronix recognizes that the internet is a global communications medium; however, laws, regulatory requirements and medical practices for medical devices vary from country to country. The information included here may not be appropriate for use outside the Canada and EU. Product availability is subject to local regulatory authority approvals.